

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been:

- accepted for use in the NHSScotland by the Scottish Medicines Consortium (SMC), and/or
- accepted for use by the NHS board's Area Drug and Therapeutics Committee (ADTC).

How does the NHS board decide which new medicines to make available for patients?

Each NHS board has an ADTC. The ADTC is responsible for advising the NHS board on all aspects of the use of medicines. ADTCs take account of national and, where applicable, local guidance when deciding which medicines should be routinely available.

What national guidance does the ADTC consider?

- SMC advises on the use of newly licensed medicines in NHSScotland. In the table, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example Healthcare Improvement Scotland provides advice on some health technology assessments, including National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs).

What local guidance does the ADTC consider?

- Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each NHS board provide advice to their ADTCs on which medicines can be routinely used. Sometimes clinical experts decide that established medicines are a better choice than new medicines.
- Medicines routinely available for use within an NHS board are usually included in the 'local formulary'. The formulary is a list of medicines for use in the NHS board that has been agreed by ADTC in consultation with local clinical experts. The formulary encourages prescribers to become familiar with a limited list of medicines which can be used to treat the majority of medical conditions.

What if a particular medicine is not routinely available in my NHS board?

- This is usually because the medicine has not been accepted by SMC for use in NHSScotland.
- There may also be differences in which medicines are preferred in NHS boards. If SMC accepts a number of medicines for which there are other medicines already available to treat a specific medical condition, the NHS board's decision may depend on clinical experts' preferences and experiences with the medicine in their local population and on local prescribing guidance. If a decision is made for a medicine not to be routinely prescribed, there are usually alternative medicines available on the formulary.
- If a medicine is not routinely available and there are no suitable formulary alternatives, a doctor can make a request to prescribe the medicine if they believe it will benefit an individual patient. All NHS boards have procedures in place to consider individual requests when a doctor considers that a medicine not included on the formulary would be the best treatment option for an individual patient.

The following table lists the NHS board's decisions on new medicines.

If you need more information on medicines decisions in your NHS board area, please email hcis.adtc-collaborative@nhs.net

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Aflibercept injection Eylea® 1186/16 http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).	Available in line with national guidance	10/10/2016
Bevacizumab infusion Avastin® 1190/16 http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf	In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	Not available as not recommended for use in NHSScotland	10/10/2016
Budesonide prolonged-release tablets Cortiment® 1093/15 http://www.scottishmedicines.org.uk/files/advice/budesonide_Cortiment_Resub_FINAL_Sept_2016_for_website.pdf	In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.	Available in line with national guidance	10/10/2016
Budesonide/Formoterol inhaler Symbicort® 1198/16 http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf	Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.	Not available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Calcipotriol, betamethasone cutaneous foam Enstilar® 1182/16 http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf	Topical treatment of psoriasis vulgaris in adults	Available in line with national guidance	10/10/2016
Carfilzomib infusion Kyprolis® 1171/16 http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not available as not recommended for use in NHSScotland	10/10/2016
Cobimetinib tablets Cotellic® 1191/16 http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf	In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not available as not recommended for use in NHSScotland	10/10/2016
Dasatinib tablets Sprycel® 1170/16 http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf	The treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase	Available in line with regional guidance for prescribing	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Dasatinib tablets Sprycel® 370/07 http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf	The treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate	Available in line with regional guidance for prescribing	10/10/2016
Fosfomycin trometamol granules for oral solution Monuril® 1163/16 http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf	Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females and prophylaxis in diagnostic and surgical transurethral procedures.	Available in line with local guidance for prescribing	10/10/2016
Golimumab injection Simponi® 1199/16 http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.	Not available as not recommended for use in NHSScotland	10/10/2016
Idarucizumab injection/infusion Praxbind® 1178/16 http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf	Reversal of anticoagulation effect of dabigatran in adults when rapid reversal is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding	Available in line with national guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Iron (III) isomaltoside 1000 injection Diafer® 1177/16 http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf	The treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.	Not available as not recommended for use in NHSScotland	10/10/2016
Lenvatinib capsules Lenvima® 1179/16 http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Available in line with regional guidance for prescribing	10/10/2016
Liraglutide injection Victoza® 1192/16 http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.	Not available as not recommended for use in NHSScotland	10/10/2016
Nivolumab infusion Opdivo® 1180/16 http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Sept_2016_FINAL_amended_150916_for_website.pdf	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Available in line with regional guidance for prescribing	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Paliperidone palmitate prolonged-release injection Trevicta® 1181/16 http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf	Maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product	Not routinely available as local clinical experts do not wish to add the medicine to formulary at this time or there is a local preference for alternative medicines	10/10/2016
Perampanel tablets Fycompa® 1200/16 http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf	Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy	Not available as not recommended for use in NHSScotland	10/10/2016
Progesterone vaginal tablets Lutigest® 1185/16 http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf	Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women	Available in line with national guidance	10/10/2016
Rilpivirine, Emtricitabine, Tenofovir alafenamide tablets Odefsey® 1189/16 http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.	Available in line with national guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Tocilizumab injection RoActemra® 1201/16 http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf	Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.	Not available as not recommended for use in NHSScotland	10/10/2016
Trametinib tablets Mekinist® 1161/16 http://www.scottishmedicines.org.uk/files/advice/trametinib_0.5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation	Available in line with regional guidance for prescribing	10/10/2016